Corcept Therapeutics (CORT) Reports Q1 2025 Earnings Results
Corcept Therapeutics (CORT) reported Q1 2025 earnings with revenue of $157.2 million, a 7% increase year-over-year, but net income declined to $20.5 million from $27.8 million. The company reiterated its 2025 revenue guidance of $900 million to $950 million and highlighted growth in its prescriber base and sales force expansion.
Tickers: $CORT
Topics: Authorized Generic Mix Average Price Decline Net Income Decline Prescriber Base Growth Revenue Growth Sales Force Expansion Stock Repurchase